Overview
- Lilly reported a blowout second quarter, with revenue up about 48% and adjusted earnings per share of $8.38, and it raised full‑year revenue and EPS guidance after the Aug. 5 earnings release.
- Foundayo had a modest U.S. debut of roughly $98 million but Lilly has filed in more than 40 countries and plans an overseas rollout in early 2027 that analysts say could drive much of the drug’s long‑term sales.
- Mounjaro showed strong international growth last quarter, with reported gains of about 55% in Europe, 30% in Japan, and 93% in China, supporting Bank of America’s view that non‑U.S. obesity markets could eventually outsize the U.S.
- Medicare’s GLP‑1 Bridge went live on July 1 and expanded coverage to about 20 million eligible beneficiaries, which has helped volume grow even as realized U.S. net sales per prescription have declined.
- Lilly disclosed positive Phase III retatrutide results and plans a U.S. filing in Q1 2027, leaving investors to watch whether new drugs and overseas launches can sustain growth as prices fall and valuation risk remains.